Table 4 Separate multiple logistic analyses of overall group and male and female subgroups to detect contributing factors to resistant nAMD

Overall (n = 46)

 Smoking (n, %)

16, 53.3

8, 50.0

0.734

0.78 (0.19–3.23)

 Typical nAMD (n, %)

15, 50.0

7, 43.8

0.549

0.65 (0.16–2.63)

 Pre-treatment VA (logMAR)

0.37 ± 0.41

0.47 ± 0.47

0.404

2.35 (0.31–17.95)

 Pre-treatment CMT (μm)

338.5 ± 134.9

348.5 ± 106.9

0.874

1.00 (0.99–1.01)

 SAF (0.1 AU increase)

2.3 ± 0.4

2.5 ± 0.5

0.490

1.06 (0.89–1.26)

(n = 17)

(n = 9)

Male (n = 26)

 Smoking (n, %)

15, 88.2

7, 77.8

0.196

0.07 (0.00–4.67)

 Typical nAMD (n, %)

8, 47.1

2, 22.2

0.293

0.30 (0.03–3.14)

 Pre-treatment VA (logMAR)

0.28 ± 0.28

0.39 ± 0.54

0.722

0.55 (0.02–14.14)

 Pre-treatment CMT (μm)

308.4 ± 64.5

342.1 ± 72.7

0.188

1.01 (0.99–1.03)

 SAF (0.1 AU increase)

2.3 ± 0.4

2.6 ± 0.2

0.013

1.57 (1.02–2.40)

(n = 13)

(n = 7)

Female (n = 20)

 Smoking (n, %)

1, 7.7

1, 14.3

0.630

2.16 (0.09–49.46)

 Typical nAMD (n, %)

7, 53.8

5, 71.4

0.669

1.63 (0.17–15.58)

 Pre-treatment VA (logMAR)

0.49 ± 0.52

0.57 ± 0.37

0.450

4.50 (0.08–245.17)

 Pre-treatment CMT (μm)

377.8 ± 188.4

356.7 ± 146.2

0.405

1.00 (0.98–1.00)

 SAF (0.1 AU increase)

2.3 ± 0.5

2.4 ± 0.7

0.874

1.01 (0.85–1.21)